Scot Barry, MS
Scot Barry, MS joined NeuroTrauma Sciences in July 2021 as Vice President of Chemistry, Manufacturing and Controls (CMC) before moving to his current role as President. Scot brings operational expertise in small molecule commercialization to the organization through his knowledge of chemical development, outsourcing/partnering management as well as regulatory and intellectual property strategy. With more than 30 years in the CDMO and biopharmaceutical industry, he has provided technical and strategic insight for a number of commercial products such as Emtricitabine and Telbivudine. He has worked for industry leaders on the CDMO side such as Pharm-Eco Laboratories (Johnson – Matthey) and Ricerca (Olon Ricerca Biosciences) where he held positions of increasing operational authority in production management and business development. He was also VP of CMC for Idenix Pharmaceuticals, an antiviral medicine leader, and led the commercial development of their hepatitis B treatment, Telbivudine. After the acquisition of Idenix by Novartis AG, Scot served as Chairman of the Joint Manufacturing Committee between the two organizations. Scot has also consulted for a number of pharmaceutical industry leaders in the areas of IP protection, post commercialization life cycle management, outsourcing strategy and operational efficiency analysis.
Scot received his BS in chemistry from Southeastern Massachusetts University and a MS in Chemistry from University of Massachusetts Amherst.